Text Size

Tumor Growth Factors in Hepatocellular Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jung-Fa,Tsai, Kaohsiung Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov Identifier:
NCT00764140
First received: February 26, 2008
Last updated: April 17, 2013
Last verified: April 2013
History of Changes
  Purpose

Malignant cells frequently produce many tumor growth factors to autocidal or endocrinal proliferate growth, metastasis,or angiogenesis about tumor cells. By studying tumor growth factors in hepatocellular carcinoma, one may know the tumor behavior, its relationship with clinical manifestation or invasion, and could be used as diagnostic or prognostic tools.This study aims to study the relationship between tumor growth factors in HCC ant its clinical relevance.


Condition Intervention
Hepatocellular Carcinoma
 Biological: tumor growth factor concentration

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Insulin-like Growth Factors (IGF) Axis (IGFs, Its Binding Proteins,Receptors), Transforming Growth Factor Alpha and Beta 1 and Epidermal Growth Factor in the Urine and Serum of Patients With Hepatocellular Carcinoma.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:

Primary Outcome Measures:
  • mortality [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • distant metastasis [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Blood and/or urine


Enrollment: 400
Study Start Date: January 2007
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
2
Specific tumor growth factors (IGFs, its binding proteins,receptors; transforming growth factor alpha and beta 1 and epidermal growth factor) in the urine and serum will be measured in patients with hepatocellular carcinoma and healthy controls
1
Patients with hepatocellular carcinoma and Healthy controls
 Biological: tumor growth factor concentration
spot urine or blood collection will be used to measure specific tumor growth factor
Other Names:
  • urine concentration of tumor growth factor
  • serum concentration of tumor growth factor

Detailed Description:

The clinical relevance of patients will be evaluated by the concentrations of tumor growth factors.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with aspiration cytology or biopsy proved HCC and sex- and age-matched healthy controls.

Criteria

Inclusion Criteria:

  • Histology proven HCC

Exclusion Criteria:

  • No definitely diagnosed tumor
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00764140

Locations
Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung, Taiwan, 807
Sponsors and Collaborators
Kaohsiung Medical University Chung-Ho Memorial Hospital
Investigators
Principal Investigator: Jung-Fa Tsai, M.D., Ph.D. Professor of Medine, Kaohsiung Medical University
  More Information

No publications provided

Responsible Party: Jung-Fa,Tsai, Professor of Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital
ClinicalTrials.gov Identifier: NCT00764140     History of Changes
Other Study ID Numbers: KMUH-IRB-960010
Study First Received: February 26, 2008
Last Updated: April 17, 2013
Health Authority: Taiwan: Department of Health

Keywords provided by Kaohsiung Medical University Chung-Ho Memorial Hospital:
tumor growth factor

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
 Neoplasms by Site
Digestive System Diseases
Liver Diseases
Mitogens
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 22, 2013